OCUMENSION THERAPEUTICS
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic therapies. The company’s vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since the inception, Ocumension Therapeutics has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. Ocumension Therapeutics believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors.
OCUMENSION THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2017-01-01
Status:
Active
Contact:
+86 (021)-61493800
Email Addresses:
[email protected]
Total Funding:
200 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Content Delivery Network Euro JsDelivr GStatic Google Static Content Pound Sterling IIS 10 Japanese Yen
Current Employees Featured
Stock Details
Investors List
General Atlantic
General Atlantic investment in Series B - Ocumension Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-04-14 | Alimera Sciences | Ocumension Therapeutics investment in Post-IPO Equity - Alimera Sciences | 20 M USD |
| 2021-01-03 | EyePoint Pharmaceuticals | Ocumension Therapeutics investment in Post-IPO Equity - EyePoint Pharmaceuticals | 15.7 M USD |
More informations about "Ocumension Therapeutics" on Search Engine
Ocumension Therapeutics, 1477:HKG summary - FT.com
3 days ago S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved. Although S&P Global Market Intelligence has made …See details»
EyePoint Pharmaceuticals and OcuMension Therapeutics
Jun 21, 2022 Follow.See details»
EyePoint Pharmaceuticals and OcuMension Therapeutics …
Jun 21, 2022 Story continues. View comments. Advertisement.See details»
Ocumension Therapeutics Announces 2021 Interim Results - PR …
Aug 20, 2021 Company loss narrowed sharply by 96%. Business Income Increased By More Than 26 Times Year-on-Year. Core Product OT-401 Approval Imminent. HONG …See details»
Alimera Sciences Receives $20 Million From Ocumension …
Apr 14, 2021 ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E to treat diabetic macular edema (DME) in patients who have been previously treated with a …See details»
Ocumension Acquires all the Equity Interests in Two Ophthalmic …
Aug 25, 2021, 00:35 ET. Share this article.See details»
Ocumension Therapeutics Announces 2022 Annual …
Mar 30, 2023 Ocumension Therapeutics Announces 2022 Annual Results. By Marie Jones March 30, 2023 7 Mins Read. Youshiying (OT-401), Company’s Core Product, Commercialized ahead of Schedule. …See details»
Ocumension Therapeutics | CipherBio
Ocumension Therapeutics add_circle edit_note Submit Changes Shanghai, China https://www.ocumension.com/en/See details»
Ocumension Therapeutics Announces 2023 Interim Results
Aug 25, 2023 More information about Ocumension Therapeutics: https://www.ocumension.com/ For the latest Stock Market news and update in the …See details»
Ocumension Therapeutics (1477.HK) - Yahoo Finance
Mountain. Loading Chart for 1477.HK. 9/21 12:03 PM. Previous Close 6.810. Open 6.840. Bid 7.000 x -- Ask 7.180 x -- Day's Range 6.840 - 7.260. 52 Week Range 4.510 - 10.400. …See details»
Ocumension Therapeutics Announces 2021 Interim Results
Aug. 20, 2021, 12:14 PM. Company loss narrowed sharply by 96% Business Income Increased By More Than 26 Times Year-on-Year. Core Product OT-401 Approval Imminent.See details»
Ocumension Therapeutics Announces CDE Approval Received …
Jul 13, 2021 News Ocumension Therapeutics. Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-101. Ocumension …See details»
Ocumension Therapeutics Announces Phase II Clinical Trial of …
Mar 14, 2024 1477 Stock. News Ocumension Therapeutics. Ocumension Therapeutics announced that, the phase II clinical trial of OT-202 , a first-in-class new drug self …See details»
Ocumension Therapeutics Announces 2022 Annual Results
Mar 30, 2023 Courageous without hesitations is always the mission Ocumension Therapeutics committed to stick with. Given that, the Group achieved remarkable …See details»
Ocumension Therapeutics Completes Phase III Trials for …
Apr 15, 2024 Ocumension Therapeutics. Equities. 1477. KYG674111011. Pharmaceuticals. Summary. Quotes. Charts. News. Ratings. Calendar. Company. …See details»
Ocumension Therapeutics ESG Risk Rating - sustainalytics.com
Feb 3, 2023 By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability …See details»
Ocumension Therapeutics Announces Approval Received for …
Oct 12, 2021 1477 Stock. News Ocumension Therapeutics. Ocumension Therapeutics Announces Approval Received for Clinical Trial of Class I New Drug OT-202 in China. …See details»
Ocumension Therapeutics
2.3 A former partner of the Company’s existing auditing firm shall be prohibited from acting as a member of the Committee for a period of one year from the date of his ceasing: (i) to …See details»
Ocumension Therapeutics | CipherBio
Explore Ocumension Therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»